Catalin Mihalcioiu

3PUBLICATIONS
61CO-AUTHORS
Molecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Jul 22, 2022
Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.

Ana Arance, Luis de la Cruz-Merino, Teresa M Petrella

|Apr 01, 2022
Spatially mapping the immune landscape of melanoma using imaging mass cytometry.

Dan Moldoveanu, LeeAnn Ramsay, Mathieu Lajoie

Pageof 1